Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3838) 3838
Publication (545) 545
Book Review (47) 47
Book Chapter (5) 5
Data Set (3) 3
Dissertation (2) 2
Magazine Article (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2986) 2986
index medicus (2467) 2467
male (1792) 1792
female (1783) 1783
adult (1505) 1505
infectious diseases (1488) 1488
sustained virological response (1321) 1321
hiv infections - drug therapy (1315) 1315
middle aged (1297) 1297
virological failure (1070) 1070
treatment outcome (1038) 1038
gastroenterology & hepatology (1006) 1006
antiviral agents - therapeutic use (986) 986
hepatitis c (985) 985
hiv (970) 970
viral load (956) 956
virology (915) 915
hepatitis c virus (875) 875
hepatitis c, chronic - drug therapy (820) 820
virological response (797) 797
immunology (783) 783
genotype (742) 742
antiviral agents (729) 729
drug therapy, combination (717) 717
antiretroviral therapy (695) 695
hiv infections - virology (682) 682
interferon (650) 650
therapy (648) 648
health aspects (646) 646
anti-hiv agents - therapeutic use (636) 636
ribavirin (631) 631
drug therapy (604) 604
pharmacology & pharmacy (582) 582
hepatitis (545) 545
aged (533) 533
care and treatment (533) 533
hepacivirus - genetics (517) 517
cd4 lymphocyte count (475) 475
ribavirin - therapeutic use (459) 459
infection (458) 458
human immunodeficiency virus--hiv (449) 449
analysis (442) 442
treatment failure (435) 435
hiv-1 - drug effects (434) 434
interferon-alpha - therapeutic use (426) 426
virus-infection (424) 424
microbiology (414) 414
antiretroviral therapy, highly active (412) 412
protease inhibitors (409) 409
research (408) 408
risk factors (401) 401
drug resistance (400) 400
hiv infection (400) 400
virus diseases (390) 390
highly active antiretroviral therapy (389) 389
retrospective studies (380) 380
biological response modifiers (374) 374
drug resistance, viral (373) 373
aids (369) 369
cohort studies (365) 365
hiv-1 - genetics (361) 361
rna, viral - blood (361) 361
active antiretroviral therapy (357) 357
cirrhosis (345) 345
human-immunodeficiency-virus (341) 341
combination therapy (339) 339
antiretroviral drugs (338) 338
mutation (333) 333
liver (332) 332
mortality (327) 327
patients (326) 326
hepatitis c - drug therapy (318) 318
hepatitis c, chronic - virology (316) 316
plus ribavirin (316) 316
genetic aspects (313) 313
young adult (313) 313
antiviral agents - administration & dosage (311) 311
viruses (305) 305
polyethylene glycols - therapeutic use (304) 304
hepacivirus - drug effects (303) 303
drug-resistance (300) 300
pegylated interferon (298) 298
hiv infections - immunology (291) 291
hepatocellular-carcinoma (289) 289
gastroenterology and hepatology (288) 288
adherence (287) 287
antiviral therapy (287) 287
time factors (284) 284
adolescent (283) 283
prospective studies (280) 280
infections (279) 279
medicine (277) 277
hcv (267) 267
liver cirrhosis (264) 264
resistance (260) 260
hiv-1 (259) 259
research article (259) 259
hiv-infected patients (251) 251
hiv-1-infected patients (250) 250
aids/hiv (246) 246
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3759) 3759
Spanish (43) 43
French (17) 17
German (6) 6
Hungarian (6) 6
Korean (5) 5
Russian (2) 2
Dutch (1) 1
Indonesian (1) 1
Italian (1) 1
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Misclassificatìon of First-Line Antiretroviral Treatment Failure Based on Immunological Monitoring of HIV Infection in Resource-Limited Settings
by Rami Kantor and Lameck Diero and Allison DeLong and Lydia Kamle and Sarah Muyonga and Fidelis Mambo and Eunice Walumbe and Wilfred Emonyi and Philip Chan and E. Jane Carter and Joseph Hogan and Nathan Buziba
Clinical Infectious Diseases, ISSN 1058-4838, 8/2009, Volume 49, Issue 3, pp. 454 - 462
Background. The monitoring of patients with human immunodeficiency virus (HIV) infection who are treated with antiretroviral medications in resource-limited... 
T lymphocytes | HIV/AIDS | Medical treatment failures | Antiretrovirals | Logistic regression | Immunology | Percentages | HIV | AIDS | Viral load | Virology | VIRAL LOAD | INFECTIOUS DISEASES | IMMUNODEFICIENCY-VIRUS-INFECTION | CD4-PERCENT | MICROBIOLOGY | DRUG-RESISTANCE | IMMUNOLOGY | VIROLOGICAL RESPONSES | SUPPRESSION | THERAPY | CD4 PERCENTAGE | CELL COUNT | LYMPHOCYTES | HIV Infections - virology | Humans | Middle Aged | Male | CD4 Lymphocyte Count | Kenya | HIV - drug effects | Viral Load | Monitoring, Immunologic - methods | Young Adult | HIV Infections - immunology | CD4-CD8 Ratio | Diagnostic Errors | Treatment Failure | Adolescent | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Aged | Antiviral agents | Patient monitoring | Care and treatment | Patient outcomes | Dosage and administration | Research | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern
by Muri, Lukas and Gamell, Anna and Ntamatungiro, Alex J and Glass, Tracy R and Luwanda, Lameck B and Battegay, Manuel and Furrer, Hansjakob and Hatz, Christoph and Tanner, Marcel and Felger, Ingrid and Klimkait, Thomas and Letang, Emilio and KIULARCO Study Grp and KIULARCO Study Group
AIDS, ISSN 0269-9370, 01/2017, Volume 31, Issue 1, pp. 61 - 70
OBJECTIVE:To investigate the prevalence and determinants of virologic failure and acquired drug resistance-associated mutations (DRMs) in HIV-infected children... 
Resistance | HIV | Africa | Resource-limited settings | Viral failure | Children | Adolescents | Antiretroviral therapy | MORTALITY | INFECTIOUS DISEASES | adolescents | antiretroviral therapy | INFECTED CHILDREN | IMMUNOLOGY | resistance | ADHERENCE | 2ND-LINE | resource-limited settings | VIROLOGY | children | VIROLOGICAL FAILURE | viral failure | HIV-1-INFECTED CHILDREN | MUTATIONS | 1ST-LINE ANTIRETROVIRAL TREATMENT | RITONAVIR | Tanzania - epidemiology | Anti-Retroviral Agents - therapeutic use | Prevalence | Prospective Studies | Cross-Sectional Studies | HIV Infections - epidemiology | HIV Infections - virology | Humans | Anti-Retroviral Agents - pharmacology | Drug Resistance, Viral | Male | HIV - isolation & purification | Mutation, Missense | Rural Population | Treatment Failure | Adolescent | Female | HIV - genetics | HIV Infections - drug therapy | Child | Clinical Science
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure
by Roger Paredes and Christina M. Lalama and Heather J. Ribaudo and Bruce R. Schackman and Cecilia Shikuma and Francoise Giguel and William A. Meyer and Victoria A. Johnson and Susan A. Fiscus and Richard T. D'Aquila and Roy M. Gulick and Daniel R. Kuritzkes and ACTG and AIDS Clinical Trials Group (ACTG) A5095 Study Team
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 5, pp. 662 - 671
Background. The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain. Methods. To... 
Polymerase chain reaction | HIV/AIDS | Antiretrovirals | RNA | Clinical trials | AIDS | Viruses | Sequencing | Genetic mutation | Virology | HIV 1 | INFECTIOUS DISEASES | EFAVIRENZ-CONTAINING REGIMENS | RANDOMIZED-TRIAL | MICROBIOLOGY | IMMUNOLOGY | PROTEASE INHIBITORS | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGICAL FAILURE | CLINICAL-TRIALS | IMMUNODEFICIENCY-VIRUS TYPE-1 | SOCIETY-USA PANEL | INFECTED PATIENTS | 2008 RECOMMENDATIONS | HIV Infections - virology | Humans | Middle Aged | Drug Resistance, Viral | HIV Reverse Transcriptase - genetics | Male | Mutation, Missense | HIV-1 - genetics | Case-Control Studies | Benzoxazines - therapeutic use | HIV-1 - classification | Polymerase Chain Reaction - methods | Randomized Controlled Trials as Topic | Medication Adherence | HIV-1 - growth & development | HIV-1 - isolation & purification | Treatment Failure | Adult | Amino Acid Substitution - genetics | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Cohort Studies | Viral drug resistance | Demographic aspects | Patient outcomes | Genetic aspects | Research | Drug therapy | HIV infection | Patient compliance | Risk factors | HIV-1 | antiretroviral resistance | minority variants | allele-specific PCR | antiretroviral therapy | quasispecies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic A cross-sectional study
by Mossoro-Kpinde, CD and Gody, JC and Bouassa, RSM and Mbitikon, O and Jenabian, MA and Robin, L and Matta, M and Zeitouni, K and Longo, JD and Costiniuk, C and Gresenguet, G and Kane, NCT and Belec, L
MEDICINE, ISSN 0025-7974, 03/2017, Volume 96, Issue 10, p. e6282
A large cohort of 220 HIV-1-infected children (median [range] age: 12 [4-17] years) was cared and followed up in the Central African Republic, including 198 in... 
VIRAL LOAD | SOUTH-AFRICA | UGANDAN CHILDREN | antiretroviral treatment | PROTEASE INHIBITORS | virological outcomes | SINGLE-DOSE NEVIRAPINE | MEDICINE, GENERAL & INTERNAL | THAN 2 YEARS | pediatrics | plasma HIV-1 RNA load | virological failure | TYPE-1 DRUG-RESISTANCE | Central Africa | HIV-INFECTED CHILDREN | resistance mutations | MEDICATION ADHERENCE | HIV-1 subtype | THYMIDINE-ANALOG MUTATIONS | HIV Infections - blood | Anti-Retroviral Agents - therapeutic use | Cross-Sectional Studies | HIV Infections - congenital | Humans | Child, Preschool | Genotype | Male | RNA, Viral - blood | HIV-1 - genetics | Viral Load | Drug Resistance, Viral - genetics | Medication Adherence | Genes, pol | Treatment Failure | Adolescent | Female | HIV Infections - drug therapy | Central African Republic | Mutation | Child | Drug resistance in microorganisms | Gene mutations | Physiological aspects | Genetic aspects | Research | HIV (Viruses) | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Dolutegravir Resistance and Failure in a Kenyan Patient
by Achieng, Loice and Riedel, David J
The Journal of Infectious Diseases, ISSN 0022-1899, 01/2019, Volume 219, Issue 1, pp. 165 - 167
INFECTIOUS DISEASES | MICROBIOLOGY | EXPERIENCED PATIENTS | IMMUNOLOGY | RALTEGRAVIR | VIROLOGICAL FAILURE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Copy-Years Viremia and Risk of Virological Failure in Long-Term–Treated HIV Patients
by Falasca, Francesca and De Vito, Corrado and Mazzuti, Laura and di Carlo, Daniele and Celani, Luigi and Fimiani, Caterina and dʼEttorre, Gabriella and Mezzaroma, Ivano and Antonelli, Guido and Turriziani, Ombretta
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2019, Volume 80, Issue 4, pp. 423 - 428
BACKGROUND:Viremia copy-years (VCY) is associated with mortality and disease outcome prediction. This study evaluated the association of VCY with virological... 
single levels of viremia | LOW-LEVEL VIREMIA | MORTALITY | INFECTIOUS DISEASES | PREDICTOR | VIRUS | RNA | AIDS | IMMUNOLOGY | INTERMITTENT VIREMIA | viremia copy-years | ACTIVE ANTIRETROVIRAL THERAPY | INFECTED PATIENTS | virological failure | HAART | Confidence intervals | Antiretroviral drugs | Level (quantity) | Viremia | Antiretroviral agents | Human immunodeficiency virus--HIV | Quartiles | Antiretroviral therapy | Target detection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD
by Jiamsakul, Awachana and Kerr, Stephen J and Ng, Oon Tek and Lee, Man Po and Chaiwarith, Romanee and Yunihastuti, Evy and Van Nguyen, Kinh and Pham, Thuy Thanh and Kiertiburanakul, Sasisopin and Ditangco, Rossana and Saphonn, Vonthanak and Sim, Benedict L. H and Merati, Tuti Parwati and Wong, Wingwai and Kantipong, Pacharee and Zhang, Fujie and Choi, Jun Yong and Pujari, Sanjay and Kamarulzaman, Adeeba and Oka, Shinichi and Mustafa, Mahiran and Ratanasuwan, Winai and Petersen, Boondarika and Law, Matthew and Kumarasamy, Nagalingeswaran and Mean, CV and Khol, V and Zhao, HX and Han, N and Li, PCK and Lam, W and Chan, YT and Saghayam, S and Ezhilarasi, C and Joshi, K and Gaikwad, S and Chitalikar, A and Wirawan, DN and Yuliana, F and Imran, D and Widhani, A and Tanuma, J and Nishijima, T and Na, S and Kim, JM and Gani, YM and David, R and Omar, SF Syed and Ponnampalavanar, S and Azwa, I and Nordin, N and Uy, E and Bantique, R and Ku, WW and Wu, PC and Lim, PL and Lee, LS and Ohnmar, PS and Ruxrungtham, K and Avihingsanon, A and Chusut, P and Sungkanuparph, S and Chumla, L and Sanmeema, N and Sirisanthana, T and Kotarathititum, W and Praparattanapan, J and Kambua, P and Sriondee, R and Bui, VH and Nguyen, THD and Cuong, DD and Ha, HL and Sohn, AH and Durier, N and Petersen, B and Jiamsakul, A and Boettiger, DC and TREAT Asia HIV Observational Datab and TREAT Asia HIV Observational Database (TAHOD) and the TREAT Asia HIV Observational Database (TAHOD)
Tropical Medicine & International Health, ISSN 1360-2276, 05/2016, Volume 21, Issue 5, pp. 662 - 674
Objectives Treatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur... 
effets indésirables | adverse events | interrupción del tratamiento | eventos adversos | antiretroviral | Asie | HIV | VIH | treatment interruptions | Asia | interruptions de traitement | antirétroviral | antirretroviral | Antiretroviral | Adverse events | Treatment interruptions | TREATMENT OUTCOMES | IMMUNOLOGICAL RESPONSE | FOLLOW-UP | DRUG-RESISTANCE | REGIMENS | ADHERENCE | TROPICAL MEDICINE | POSITIVE INDIVIDUALS | OBSERVATIONAL DATABASE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | VIROLOGICAL FAILURE | ACTIVE ANTIRETROVIRAL THERAPY | Medication Adherence - statistics & numerical data | Medication Adherence - psychology | Prospective Studies | Drug Administration Schedule | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Male | Treatment Outcome | CD4 Lymphocyte Count | Disease Progression | Viral Load | Anti-HIV Agents - administration & dosage | Time Factors | Treatment Failure | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Antiviral agents | HIV (Viruses) | AIDS treatment | Analysis | Antiretroviral drugs | Human immunodeficiency virus--HIV | Medical treatment | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
by Gregson, John and Tang, Michele and Ndembi, Nicaise and Hamers, Raph L and Rhee, Soo-Yon and Marconi, Vincent C and Diero, Lameck and Brooks, Katherine A and Theys, Kristof and Rinke de Wit, Tobias and Arruda, Monica and Garcia, Frederico and Monge, Susana and Günthard, Huldrych F and Hoffmann, Christopher J and Kanki, Phyllis J and Kumarasamy, Nagalingeshwaran and Kerschberger, Bernard and Mor, Orna and Charpentier, Charlotte and Todesco, Eva and Rokx, Casper and Gras, Luuk and Helvas, Elias K and Sunpath, Henry and Di Carlo, Domenico and Antinori, Antonio and Andreoni, Massimo and Latini, Alessandra and Mussini, Cristina and Aghokeng, Avelin and Sonnerborg, Anders and Neogi, Ujjwal and Fessel, William J and Agolory, Simon and Yang, Chunfu and Blanco, Jose L and Juma, James M and Smit, Erasmus and Schmidt, Daniel and Watera, Christine and Asio, Juliet and Kurungi, Wilford and Tostevin, Anna and El-Hay, Tal and Clumeck, Nathan and Goedhals, Dominique and Van Vuuren, Cloete and Bester, Philip A and Sabin, Caroline and Mukui, Irene and Santoro, MARIA M and Perno, Carlo F and Hunt, Gillian and Morris, Lynn and Camacho, Ricardo and De Oliveira, Tulio and Pillay, Deenan and Schulter, Eugene and Murakami-Ogasawara, Akio and Reyes-Terán, Gustavo and Romero, Karla and Avila-Rios, Santiago and Sirivichayakul, Sunee and Ruxrungtham, Kiat and Mekprasan, Suwanna and Dunn, David and Kaleebu, Pontiano and Raizes, Elliot and Kantor, Rami and Shafer, Robert W and Gupta, Ravindra K and TenoRes Study Grp
The Lancet Infectious Diseases, ISSN 1473-3099, 2016, Volume 16, Issue 5, pp. 565 - 575
Summary Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure... 
Infectious Disease | LAMIVUDINE | INFECTIOUS DISEASES | TENOFOVIR DISOPROXIL FUMARATE | NAIVE PATIENTS | VIROLOGICAL FAILURE | EFAVIRENZ | EMTRICITABINE | IMMUNODEFICIENCY-VIRUS TYPE-1 | ANTIRETROVIRAL THERAPY | HIV-1-INFECTED PATIENTS | SUBTYPE C | Antiviral agents | Medical research | Analysis | Medicine, Experimental | Drug resistance | HIV (Viruses) | Health aspects | Epidemiology | Prevention | Tenofovir | Pyrimidines | AIDS treatment | Risk factors | Studies | Antiretroviral drugs | Protease inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011-2015
by Zhao, Yan and Wu, Zunyou and McGoogan, Jennifer M and Sha, Yiyi and Zhao, Decai and Ma, Ye and Brookmeyer, Ron and Detels, Roger and Montaner, Julio S G
Clinical Infectious Diseases, ISSN 1058-4838, 01/2019, Volume 68, Issue 1, pp. 43 - 50
Initiating antiretroviral therapy (ART) quickly after diagnosis (i.e., within 30 days) was associated with significantly reduced treatment dropout and... 
HIV/AIDS | virological failure | treatment dropout | antiretroviral therapy | China | MORTALITY | INFECTIOUS DISEASES | INITIATION | RETENTION | MICROBIOLOGY | IMMUNOLOGY | CARE | COUNTS | TREATMENT PROGRAM | HIV VIRAL LOAD | INFECTION | OUTCOMES | IMMUNODEFICIENCY | and Commentaries | HIV | AIDS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
by Wijting, IEA and Rutsaert, SL and Rokx, C and Burger, DM and Verbon, A and Kampen, JJA and Boucher, CAB and Rijnders, BJA and Vandekerckhove, L
HIV Medicine, ISSN 1464-2662, 01/2019, Volume 20, Issue 1, pp. 63 - 68
Objectives The Dolutegravir Monotherapy for HIV (DOMONO; NCT02401828) study showed that maintenance monotherapy with dolutegravir (DTG) is associated with... 
HIV‐1 | virological failure | HIV integrase inhibitors | combination antiretroviral therapy | dolutegravir monotherapy | HIV-1 | INFECTIOUS DISEASES | RESERVOIR | RALTEGRAVIR | DNA | DOUBLE-BLIND | HIV-1 INFECTION | NAIVE ADULTS | PCR | Therapy | Identification methods | Copy number | Lamivudine | Maintenance | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | CD4 antigen | Antiretroviral agents | Human immunodeficiency virus--HIV | Peripheral blood mononuclear cells | Diagnosis | Deoxyribonucleic acid--DNA | Short Communications | Short Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation
by Claudie Laprise and Alexandra de Pokomandy and Jean-Guy Baril and Serge Dufresne and Helen Trottier
Clinical Infectious Diseases, ISSN 1058-4838, 11/2013, Volume 57, Issue 10, pp. 1489 - 1496
Background. The current goal of antiretroviral therapy (ART) is to maintain a suppressed human immunodeficiency virus (HIV) viral load below limits of assay... 
HIV/AIDS | Antiretrovirals | HIV infections | HIV | RNA | Viremia | Health care industry | Viral load | Disease risks | Virology | Arts | Virological failure | Low-level viremia | Cohort study | low-level viremia | INFECTIOUS DISEASES | cohort study | INTERMITTENT | MICROBIOLOGY | IMMUNOLOGY | SUPPRESSION | viral load | ACTIVE ANTIRETROVIRAL THERAPY | RESISTANCE | INFECTED PATIENTS | virological failure | HIV Infections - virology | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Viremia - drug therapy | Viral Load | Incidence | Viremia - virology | Treatment Failure | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Cohort Studies | Measurement | Care and treatment | Research | HIV infection | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Prevalence of HIV-1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa
by Vincent C. Marconi and Henry Sunpath and Zhigang Lu and Michelle Gordon and Kofi Koranteng-Apeagyei and Jane Hampton and Steve Carpenter and Janet Giddy and Douglas Ross and Helga Hoist and Elena Losina and Bruce D. Walker and Daniel R. Kuritzkes and S Africa Resistance Cohort Study T and South Africa Resistance Cohort Study Team
Clinical Infectious Diseases, ISSN 1058-4838, 5/2008, Volume 46, Issue 10, pp. 1589 - 1597
Background. Emergence of human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of antiretroviral therapy in resource-limited... 
HIV/AIDS | Highly active antiretroviral therapy | Antiretrovirals | Viruses | AIDS | Reverse transcriptase inhibitors | Infections | Drug resistance | Genetic mutation | HIV 1 | Virology | INFECTIOUS DISEASES | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | VIROLOGICAL RESPONSE | ADHERENCE | REVERSE-TRANSCRIPTASE INHIBITORS | IMMUNODEFICIENCY-VIRUS TYPE-1 | VERTICAL TRANSMISSION | RECEIVING NEVIRAPINE | MUTATIONS | SUBTYPE-B | PROTEASE | Anti-HIV Agents - pharmacology | HIV-1 - drug effects | HIV Infections - virology | Humans | Middle Aged | Drug Resistance, Viral | Genotype | Male | RNA, Viral - blood | Mutation, Missense | HIV-1 - genetics | HIV-1 - classification | Antiretroviral Therapy, Highly Active | RNA, Viral - genetics | HIV-1 - isolation & purification | Adult | Amino Acid Substitution - genetics | Female | HIV Infections - drug therapy | South Africa | RNA, Viral - isolation & purification | Drug resistance in microorganisms | Complications and side effects | Research | Drug therapy | Statistics | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights